Sanofi Share Holder Equity 2010-2024 | SNY

Sanofi share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Sanofi share holder equity for the quarter ending March 31, 2024 was $M, a NAN% increase year-over-year.
  • Sanofi share holder equity for 2023 was $80.472B, a 1.63% increase from 2022.
  • Sanofi share holder equity for 2022 was $79.18B, a 3.05% decline from 2021.
  • Sanofi share holder equity for 2021 was $81.671B, a 13.22% increase from 2020.
Sanofi Annual Share Holder Equity
(Millions of US $)
2023 $80,472
2022 $79,180
2021 $81,671
2020 $72,133
2019 $66,201
2018 $69,720
2017 $65,849
2016 $63,877
2015 $64,636
2014 $74,797
2013 $75,732
2012 $73,915
2011 $78,539
2010 $70,761
2009 $67,563
Sanofi Quarterly Share Holder Equity
(Millions of US $)
2024-03-31
2023-12-31 $80,472
2023-09-30
2023-06-30 $79,541
2023-03-31
2022-12-31 $79,180
2022-09-30
2022-06-30 $75,882
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $65,849
2017-09-30
2017-06-30 $63,583
2017-03-31
2016-12-31 $63,877
2016-09-30
2016-06-30 $61,390
2016-03-31
2015-09-30
2015-06-30 $62,803
2014-06-30 $71,014
2013-06-30 $73,385
2012-06-30 $72,421
2012-03-31 $0
2011-12-31 $78,539
2011-09-30
2011-06-30 $75,685
2011-03-31
2010-12-31 $70,761
2010-09-30
2010-06-30 $67,088
2010-03-31
2009-12-31 $67,563
2009-09-30
2009-06-30 $61,000
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11